A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab
Open Access
- 23 June 2020
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (2), 702-707
- https://doi.org/10.1159/000507955
Abstract
A 71-year-old woman was diagnosed with advanced gastroesophageal junction cancer with bulky lymph nodes along the cardiac region and the lower mediastinum (GE-Circ type 3 T3 N3 M0 H0 stage III) and received treatment with S-1 and oxaliplatin (SOX) as first-line chemotherapy. After 3 cycles of SOX, severe anorexia and diarrhea were observed. We converted from this regimen of systemic chemotherapy to ramucirumab (RAM) monotherapy as second-line chemotherapy. This treatment resulted in a reduction in size of the metastatic lymph nodes along the cardiac region and the lower mediastinum. However, progression of lymph node metastasis and the primary tumor was observed following 7 months of RAM monotherapy. Therefore, nivolumab was initiated as third-line chemotherapy 14 months after the initial treatment. After 3 months of nivolumab administration, a 47% reduction in metastatic lymph nodes was achieved and a regression of the primary gastric tumor as seen on an enhanced computed tomography scan. After 7 months of nivolumab monotherapy, the diameter of the target lymph nodes had reduced by 81% from baseline, and there was no evidence of malignancy upon pathological assessment of the primary tumor site biopsy. The patient survived with nivolumab monotherapy for approximately 2 years after her first visit, without any adverse reaction to nivolumab.Keywords
This publication has 10 references indexed in Scilit:
- Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective studyOncotarget, 2018
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Japanese gastric cancer treatment guidelines 2014 (ver. 4)Gastric Cancer, 2016
- Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysisJournal of Gastroenterology and Hepatology, 2016
- Comparison on Clinicopathological Features and Prognosis Between Esophagogastric Junctional Adenocarcinoma (Siewert II/III Types) and Distal Gastric AdenocarcinomaMedicine, 2015
- Global Patterns of Cancer Incidence and Mortality Rates and TrendsCancer Epidemiology, Biomarkers & Prevention, 2010
- Trends in incidence of oesophageal and stomach cancer subtypes in EuropeEuropean Journal of Gastroenterology & Hepatology, 2009
- Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in JapanJournal of Gastroenterology and Hepatology, 2008
- Adenocarcinoma of the Esophago-Gastric JunctionScandinavian Journal of Surgery, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000